<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197833</url>
  </required_header>
  <id_info>
    <org_study_id>VAP.VV017</org_study_id>
    <nct_id>NCT01197833</nct_id>
  </id_info>
  <brief_title>Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities</brief_title>
  <acronym>017</acronym>
  <official_title>A Multicenter, Randomized, Blinded Study of Endovenous Thermal Ablation With or Without Varisolve™ Polidocanol Endovenous Microfoam (PEM) Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and
      may cause discomfort. In this study, patients with varicose veins in the legs will be
      participating. The purpose of this research study is to evaluate the safety and effectiveness
      of two different doses of an investigational drug, Polidocanol Endovenous Microfoam (PEM)
      compared to vehicle (inactive solution) when used following an approved heat treatment in
      subjects with varicose veins.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score)</measure>
    <time_frame>IPR-V3 measured at baseline and then at 8 weeks</time_frame>
    <description>The Independent Photography Review - Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient's visible varicose veins. At screening, the site clinician was instructed to review the appearance of the patient's varicose veins in the medial section of each leg (a 'live' assessment), then select an IPR-V3 score (i.e., none=0, mild, moderate, severe or very severe=4) that best represented the appearance of the patient's varicose veins. This assessment took into account the attributes caliber, dilatation, tortuosity, and extent and number of varicosities, and was used to determine patient eligibility. The site clinician used a set of reference photographs (2 example photographs for each score on the scale) to assist with assigning a score to the appearance of the patient's visible varicose veins.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change From Baseline in PA-V3 Score</measure>
    <time_frame>PA-V3 measured at baseline and then at 8 weeks</time_frame>
    <description>The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this paper questionnaire, the instructions included a diagram of the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from &quot;Not at all noticeable&quot; (a score of 0) to &quot;Extremely noticeable&quot; (a score of 4)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Great Saphenous Vein Incompetence</condition>
  <condition>Visible Varicosities</condition>
  <arm_group>
    <arm_group_label>Endovenous ablation+polidocanol injectable microfoam 0.125%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endovenous ablation+polidocanol injectable micrfoam, 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endovenous ablation+vehicle (placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>endovenous ablation followed by injection of vehicle (placebo) to target vein</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endovenous ablation+polidocanol injectable microfoam 0.125%</intervention_name>
    <description>All components except API</description>
    <arm_group_label>Endovenous ablation+polidocanol injectable microfoam 0.125%</arm_group_label>
    <other_name>endovenous ablation followed by polidocanol endovenous microfoam 0.125% injection to target vein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endovenous ablation+polidocanol injectable microfoam 1.0%</intervention_name>
    <description>endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%</description>
    <arm_group_label>Endovenous ablation+polidocanol injectable micrfoam, 1.0%</arm_group_label>
    <other_name>Endovenous ablation followed by injection of polidocanol injectable foam 1.0% to target vein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endovenous ablation+polidocanol injectable foam 2.0%</intervention_name>
    <description>Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%</description>
    <arm_group_label>endovenous ablation+vehicle (placebo)</arm_group_label>
    <other_name>Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Incompetence of SFJ

          -  Patients who are candidates for ETA [laser or radiofrequency ablation (RFA)]

          -  Symptomatic varicose veins

          -  Visible varicose veins

          -  Ability to comprehend and sign an informed consent and complete study questionnaires
             in English

        Exclusion Criteria:

          -  Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as
             assessed by CEAP Classification of Venous Disorders)

          -  Patients who have active ulceration on the leg to be treated (Clinical Finding C6, as
             assessed by CEAP Classification of Venous Disorders)

          -  Leg obesity impairing the ability to access the vein to be treated and/or to apply
             post-procedure compression bandaging and stockings

          -  Ultrasonographic or other evidence of current or previous deep vein thrombosis or
             occlusion

          -  Deep venous reflux unless clinically insignificant in comparison to superficial reflux

          -  Peripheral arterial disease precluding the wearing of post-procedure compression
             bandaging and stockings

          -  Reduced mobility

          -  History of deep vein thrombosis, pulmonary embolism or stroke, including evidence of
             prior DVT on duplex ultrasound

          -  Major surgery, prolonged hospitalization or pregnancy within 3 months of screening

          -  Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic
             insufficiency; serious skin disease/condition that may compromise the ability of the
             patient to comply with the compression protocol, etc.)

          -  Known allergic response to polidocanol or heparin, including history of
             heparin-induced thrombocytopenia, and/or multiple allergic reactions

          -  Current alcohol or drug abuse

          -  Pregnant or lactating women

          -  Women of childbearing potential not using effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Tonawanda</city>
        <state>New York</state>
        <zip>14120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <results_first_submitted>February 7, 2014</results_first_submitted>
  <results_first_submitted_qc>September 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2014</results_first_posted>
  <disposition_first_submitted>July 23, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>December 9, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 9, 2014</disposition_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>varicose veins</keyword>
  <keyword>Great saphenous vein</keyword>
  <keyword>varicosities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polidocanol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Endovenous Ablation, Vehicle Placebo</title>
          <description>Endovenous ablation followed by vehicle placebo</description>
        </group>
        <group group_id="P2">
          <title>Endovenous Ablation, Polidocanol Injectable Foam, 0.5%</title>
          <description>Endovenous ablation followed by polidocanol injectable foam, 0.5%</description>
        </group>
        <group group_id="P3">
          <title>Endovenous Ablation, Polidocanol Injectable Foam 1.0%</title>
          <description>endovenous ablation followed by polidocanol injectable foam 1.0%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>all treated patients</population>
      <group_list>
        <group group_id="B1">
          <title>Endovenous Ablation, Vehicle Placebo</title>
          <description>Endovenous ablation followed by vehicle placebo</description>
        </group>
        <group group_id="B2">
          <title>Endovenous Ablation, Polidocanol Injectable Foam, 0.5%</title>
          <description>Endovenous ablation followed by polidocanol injectable foam, 0.5%</description>
        </group>
        <group group_id="B3">
          <title>Endovenous Ablation, Polidocanol Injectable Foam 1.0%</title>
          <description>endovenous ablation followed by polidocanol injectable foam 1.0%</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="12.05"/>
                    <measurement group_id="B2" value="50.1" spread="11.60"/>
                    <measurement group_id="B3" value="51.8" spread="9.75"/>
                    <measurement group_id="B4" value="52.0" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg^m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="6.04"/>
                    <measurement group_id="B2" value="27.7" spread="4.58"/>
                    <measurement group_id="B3" value="28.1" spread="5.25"/>
                    <measurement group_id="B4" value="28.3" spread="5.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score)</title>
        <description>The Independent Photography Review – Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient’s visible varicose veins. At screening, the site clinician was instructed to review the appearance of the patient’s varicose veins in the medial section of each leg (a ‘live’ assessment), then select an IPR-V3 score (i.e., none=0, mild, moderate, severe or very severe=4) that best represented the appearance of the patient’s varicose veins. This assessment took into account the attributes caliber, dilatation, tortuosity, and extent and number of varicosities, and was used to determine patient eligibility. The site clinician used a set of reference photographs (2 example photographs for each score on the scale) to assist with assigning a score to the appearance of the patient’s visible varicose veins.</description>
        <time_frame>IPR-V3 measured at baseline and then at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endovenous Ablation, Vehicle Placebo</title>
            <description>Endovenous ablation followed by vehicle placebo</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Ablation, Polidocanol Injectable Foam, 0.5%</title>
            <description>Endovenous ablation followed by polidocanol injectable foam, 0.5%</description>
          </group>
          <group group_id="O3">
            <title>Endovenous Ablation, Polidocanol Injectable Foam 1.0%</title>
            <description>endovenous ablation followed by polidocanol injectable foam 1.0%</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score)</title>
          <description>The Independent Photography Review – Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient’s visible varicose veins. At screening, the site clinician was instructed to review the appearance of the patient’s varicose veins in the medial section of each leg (a ‘live’ assessment), then select an IPR-V3 score (i.e., none=0, mild, moderate, severe or very severe=4) that best represented the appearance of the patient’s varicose veins. This assessment took into account the attributes caliber, dilatation, tortuosity, and extent and number of varicosities, and was used to determine patient eligibility. The site clinician used a set of reference photographs (2 example photographs for each score on the scale) to assist with assigning a score to the appearance of the patient’s visible varicose veins.</description>
          <units>score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.102"/>
                    <measurement group_id="O2" value="-1.30" spread="0.100"/>
                    <measurement group_id="O3" value="-1.11" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in PA-V3 Score</title>
        <description>The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this paper questionnaire, the instructions included a diagram of the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from “Not at all noticeable” (a score of 0) to “Extremely noticeable” (a score of 4)</description>
        <time_frame>PA-V3 measured at baseline and then at 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Endovenous Ablation, Vehicle Placebo</title>
            <description>Endovenous ablation followed by vehicle placebo</description>
          </group>
          <group group_id="O2">
            <title>Endovenous Ablation, Polidocanol Injectable Foam, 0.5%</title>
            <description>Endovenous ablation followed by polidocanol injectable foam, 0.5%</description>
          </group>
          <group group_id="O3">
            <title>Endovenous Ablation, Polidocanol Injectable Foam 1.0%</title>
            <description>endovenous ablation followed by polidocanol injectable foam 1.0%</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in PA-V3 Score</title>
          <description>The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this paper questionnaire, the instructions included a diagram of the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from “Not at all noticeable” (a score of 0) to “Extremely noticeable” (a score of 4)</description>
          <units>score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="0.142"/>
                    <measurement group_id="O2" value="-1.81" spread="0.140"/>
                    <measurement group_id="O3" value="-1.85" spread="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Endovenous Ablation, Vehicle Placebo</title>
          <description>Endovenous ablation followed by vehicle placebo</description>
        </group>
        <group group_id="E2">
          <title>Endovenous Ablation, Polidocanol Injectable Foam, 0.5%</title>
          <description>Endovenous ablation followed by polidocanol injectable foam, 0.5%</description>
        </group>
        <group group_id="E3">
          <title>Endovenous Ablation, Polidocanol Injectable Foam 1.0%</title>
          <description>endovenous ablation followed by polidocanol injectable foam 1.0%</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>infusion site thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>edema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>limb discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>pain in extermity</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="38"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Wright MB FRCS</name_or_title>
      <organization>BTG International Inc</organization>
      <phone>610-278-1660</phone>
      <email>david.wright@btgplc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

